Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40213 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL1104745 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL23044637 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL30233044 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL409084 | 0.96 | HTR2A (0.56) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL125510 | 0.93 | HTR2A (0.56) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL10062010 | 0.93 | HTR2A (0.56) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL30232973 | 0.89 | BCL9 (0.57) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL916518 | 0.89 | BCL9 (0.57) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL409598 | 0.88 | HTR2A (0.59) | HTR2ABCL9CTNNB1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4234016-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3921327-B1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX INC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4021912-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20220106354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| WO-2021035360-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-04 | — | — | WO | disclosed |
| US-8586705-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2012-11-29 | — | — | US | disclosed |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2012-11-29 | — | — | US | disclosed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| WO-2007048190-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | ABL1, FLT3, SRC | HTR2A 4073/4885BCL9 849/4885CTNNB1 3582/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | HTR2A 4352/4885BCL9 3646/4885CTNNB1 1816/4885 |
| US-20220106354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | HSD11B2, HSD11B1, NR3C2 | HTR2A 3436/4885BCL9 3463/4885CTNNB1 3109/4885 |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | MICA, PICALM, CLTB | HTR2A 2682/4885BCL9 1912/4885CTNNB1 4529/4885 |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | MICA, PICALM, CLTB | HTR2A 2682/4885BCL9 1912/4885CTNNB1 4529/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | HTR2A 3436/4885BCL9 3463/4885CTNNB1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.